Swelling (mean) · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Function: walking disability during first 6 hours · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Global assessment of treatment success · acute gout
NSAIDs showed no clear difference in patients' global assessment of treatment success at day 3 to 4 compared with glucocorticoids (moderate certainty).
1 finding from 1 review
RR 0.92 [0.7, 1.22]
Studies not reported
Moderate
HRQOL ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Inflammation: participants with no swelling at 72 hours (canakinumab 150 mg) Assessed by the investigator as no swelling, mild/palpable, moderate/visible, severe/bulging beyond the joint margins · acute gout
NSAIDs showed no clear difference in inflammation: swelling compared with placebo (low certainty).
1 finding from 1 review
RR 1.08 [0.79, 1.49]
Studies not reported
Low
Withdrawals due to adverse events · acute gout
NSAIDs showed no clear difference in withdrawals due to adverse events compared with glucocorticoids (moderate certainty).
1 finding from 1 review
RR 2.8 [0.55, 14.22]
Studies not reported
Moderate
Total adverse events · acute gout
NSAIDs probably leads to higher total adverse events compared with glucocorticoids (moderate certainty).
1 finding from 1 review
RR 1.62 [1.03, 2.55]
Studies not reported
Moderate
Function: ≥ 50% improvement in pain with movement at 24 hours · acute gout
NSAIDs showed no clear difference in function: ≥ 50% improvement in pain with movement at 24 hours compared with placebo (low certainty).
1 finding from 1 review
RR 4 [0.5, 31.74]
Studies not reported
Low
Participants' global assessment of treatment: not measured№. of participants: 30 (1 RCT) · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Health‐related quality of life: not measured№. of participants: 30 (1 RCT) · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Withdrawals due to adverse events · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Total adverse events · acute gout
NSAIDs showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
RR 0.2 [0.01, 3.85]
Studies not reported
Low
Pain intensity VAS (0 to 100; 0 = no pain, 100 = worst pain) · Patients with acute low‐back pain
1 finding from 1 review
Disability RMDQ (0 to 24; lower = better) · Patients with acute low‐back pain
1 finding from 1 review
Proportion of participants experiencing global improvement % of dichotomized Likert scale · Patients with acute low‐back pain
NSAIDs may leads to higher proportion of participants experiencing global improvement Various… compared with placebo (low certainty).
1 finding from 1 review
Proportion of participants experiencing adverse events · Patients with acute low‐back pain
It is very uncertain whether NSAIDs changes proportion of participants experiencing adverse events compared with placebo (very low certainty).
1 finding from 1 review
Return to work · Patients with acute low‐back pain
It is very uncertain whether NSAIDs changes return to work (%) compared with placebo (very low certainty).
1 finding from 1 review
MBL (mL per cycle) · women with heavy menstrual bleeding
1 finding from 1 review
Proportion of women with no subjective improvement in MBL · women with heavy menstrual bleeding
NSAIDs showed no clear difference in proportion of women with no subjective improvement in MBL compared with ethamsylate (control) (low certainty).
1 finding from 1 review
Number of days' bleeding · women with heavy menstrual bleeding
1 finding from 1 review